23andMe’s $305M Sale To Co-Founder Wojcicki Approved: California Loses Legal Battle Over DNA Privacy

A U.S. bankruptcy judge has cleared 23andMe’s $305 million sale to TTAM Research, a nonprofit led by co-founder Anne Wojcicki, rejecting California’s attempt to delay the deal over privacy concerns. 

Judge Brian Walsh said California’s appeal is likely to fail and that consumers remain free to delete their data, according to a Reuters report.

On July 2, 23andMe confirmed the sale of “substantially all” of its assets, including its core Personal Genome Service, research unit, and Lemonaid Health, to TTAM. 

The transaction, approved by the U.S. Bankruptcy Court for the Eastern District of Missouri, is expected to close in the coming weeks.

California, backed by states like New York and Texas, argued the sale violated genetic privacy laws and could lead to the unauthorized transfer of DNA data. 

The state said 1.8 million California customers were affected. 

Walsh dismissed the concerns, citing existing user rights and TTAM’s commitment to upholding privacy policies.

TTAM outbid Regeneron Pharmaceuticals' $256 million offer in a court-supervised process. 

Wojcicki, who resigned as CEO earlier this year to make an independent bid, said operating as a nonprofit will better align with 23andMe’s mission to promote public understanding of DNA.

On Stocktwits, retail sentiment for 23andMe was ‘bearish’ amid ‘extremely low’ message volume.

23andMe’s stock has risen 35.8% so far in 2025.

For updates and corrections, email newsroom[at]stocktwits[dot]com.